(Q39187610)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24854989%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

How to manage mantle cell lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24854989%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24854989%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Simone Ferrero

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24854989%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

M Dreyling

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24854989%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

23 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24854989%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24854989%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24854989%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24854989%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

2117-2130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24854989%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2014.171

19 March 2020

exact match

0 references

cites work

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Treatment of older patients with mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

CDK4andMDM2Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-typeINK4a/ARFLocus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Risk factors of central nervous system relapse in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Outcome of deferred initial therapy in mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.171

High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen

21 January 2018

1 reference

12 December 2020

p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas

1 reference

12 December 2020

High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience

1 reference

12 December 2020

Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen.

1 reference

12 December 2020

Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy

1 reference

12 December 2020

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

12 December 2020

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

12 December 2020

Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)

1 reference

12 December 2020

Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen

1 reference

12 December 2020

The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival

1 reference

12 December 2020

Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

12 December 2020

Utility of positron emission tomography scans in mantle cell lymphoma

1 reference

12 December 2020

Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group

1 reference

12 December 2020

Mantle-cell lymphoma: a population-based clinical study.

1 reference

12 December 2020

Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma

1 reference

12 December 2020

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS

1 reference

12 December 2020

Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

1 reference

12 December 2020